Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2019 07:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH

Company will hold investor event on December 9 at 12:30 PM CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical...
October 01, 2019 07:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
September 26, 2019 12:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
September 24, 2019 07:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise

CAMBRIDGE, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
August 21, 2019 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Participate in Two Investor Conferences

CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
August 07, 2019 16:05 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results

Data presented at ASCO and EHA suggest potential disease-modifying activity of CPI-0610 across the spectrum of myelofibrosis (MF) parameters, with multiple potential pathways for approval The EZH2...
June 13, 2019 14:57 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference

CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
June 12, 2019 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209

CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Jacob Stuckey, Senior Scientist at Constellation Pharmaceuticals,...
June 03, 2019 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients

CPI-0610 showed signals of clinical activity, both as a monotherapy and in combination with ruxolitinib, in refractory myelofibrosis (MF) patientsPatients treated with CPI-0610 exhibited improvement...
May 31, 2019 11:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right